CCN1, a novel RA target?

Barranco, Caroline

doi:10.1038/nrrheum.2016.138

Cited by 6 publications

(6 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…has been linked to a few clinical conditions, such as cancer, atherosclerosis, arthritis, and fibrosis (34)(35)(36)(37). CCN1 was activated by lots of growth factors including TGF-β1, FGF2, GH, etc (38).…”

Section: Discussionmentioning

confidence: 99%

“…CCN1 is a multifunctional protein, playing a pivotal role in diverse physiological processes, including embryonic development, aging, vascular maintenance, and tissue damage repair (32,33). Additionally, CCN1 has been linked to a few clinical conditions, such as cancer, atherosclerosis, arthritis, and fibrosis (34)(35)(36)(37). CCN1 was activated by lots of growth factors including TGF-β1, FGF2, GH, etc (38).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Melatonin serves as a novel treatment in cystic fibrosis and inhibits cystic fibrosis through TGF-β1/Smad and EMT

Zhang,

Gong,

et al. 2023

Preprint

View full text Add to dashboard Cite

BackgroundMelatonin (MEL) is an indole amine molecule primarily produced in the pineal gland. Melatonin has been shown in numerous studies to have anti-fibrosis characteristics in the kidney, liver, and other organs. However, it is still unclear how melatonin works in bladder fibrosis. We explored how melatonin affected animals with bladder fibrosis and its underlying mechanisms.Materials and MethodsMEL was used to treat human bladder smooth muscle cells (HBdSMCs) after they were stimulated with TGF-β1 in vitro. Proteomic analysis and then bioinformatic analysis based on the alterations in these proteins were then performed on HBdSMCs from the different processing methods. To construct an in vivo bladder fibrosis model, we injected protamine sulfate (PS) and lipopolysaccharide (LPS) twice a week into the rat bladder for six weeks. After two weeks of PS/LPS treatment, the treatment group was treated with MEL (20mg/kg/d) for 4 weeks. Finally, we detected the expression of fibrosis markers from different perspectives. The TGF-β1/Smad pathway, and EMT in cell and bladder tissues were also identified. Further proteomic analysis was also performed.ResultsIn the in vitro experiment, we found that TGF-β1 treatment enhanced the fibrosis markers Collagen III and α-SMA of HBdSMCs. E-cadherin expression decreased while TGF-β1/Smad pathway was activated. Vimentin and N-cadherin expressions were also elevated at the same time. Similar findings were observed in the LPS group. After MEL treatment, the expression of collagen III and α-SMA decreased, and the expression of E-cadherin increased, while the expression of Vimentin and N-cadherin also decreased. CCN1 and SQLE may be the important proteins in the development of bladder fibrosis, according to quantitative proteomics analysis. MEL can decrease their expressions which leadis to relief of bladder fibrosis. Bioinformatics analysis shows that the extracellular space structure related to metabolic pathways, actin filament binding, and stress fibers can serve as a pivotal focus in the management of fibrosis.ConclusionMelatonin attenuates bladder fibrosis by blocking the TGF-β1/Smad pathway and EMT. CCN1 appears to be a possible therapeutic target for bladder fibrosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Melatonin serves as a novel treatment in cystic fibrosis and inhibits cystic fibrosis through TGF-β1/Smad and EMT

Zhang,

Gong,

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Accumulated data suggested CCN1 is a multifunctional protein, which is essential for physiological processes such as embryonic development, tissue injury repair, senescence, and angiogenesis [24,25]. Later, CCN1 was also found to participate in pathological processes, including but not limited to arthritis, fibrosis, atherosclerosis, and cancer [26][27][28][29][30]. CCN1 is a rapid response gene to a wide range of stimulation.…”

Section: Ccn1mentioning

confidence: 99%

The Roles of CCN1/CYR61 in Pulmonary Diseases

Zhu

Almuntashiri

Han

et al. 2020

IJMS

View full text Add to dashboard Cite

CCN1 (cysteine-rich 61, connective tissue growth factor, and nephroblastoma-1), previously named CYR61 (cysteine-rich angiogenic inducer 61) belongs to the CCN family of matricellular proteins. CCN1 plays critical roles in the regulation of proliferation, differentiation, apoptosis, angiogenesis, and fibrosis. Recent studies have extensively characterized the important physiological and pathological roles of CCN1 in various tissues and organs. In this review, we summarize both basic and clinical aspects of CCN1 in pulmonary diseases, including acute lung injury (ALI), chronic obstructive pulmonary disease (COPD), lung fibrosis, pulmonary arterial hypertension (PAH), lung infection, and lung cancer. We also emphasize the important challenges for future investigations to better understand the CCN1 and its role in physiology and pathology, as well as the questions that need to be addressed for the therapeutic development of CCN1 antagonists in various lung diseases.

show abstract

“…CCN genes have been linked to the pathophysiology of chronic inflammatory disorders like rheumatoid arthritis (RA), neuroinflammatory diseases, and inflammatory kidney disease (8) . CCN1 is a crucial proinflammatory mediator in RA based on increased levels of CCN1 in synovial fluid from RA patients (9) . By stimulating the generation of monocyte chemoattractant protein-1 in osteoblasts, CCN1 promotes monocyte movement (10) .…”

Section: Introductionmentioning

confidence: 99%

Peripheral Blood mRNA and Protein Levels of CCN1 and CCN3 in Psoriatic Arthritis: A Case-Control Study

Esawy¹,

Kotb²,

Baioumy³

et al. 2023

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Patients with psoriasis may develop psoriatic arthritis (PsA), an inflammatory joint disorder. Measuring cellular communication network (CCN) expression levels can help in disease diagnosis and prognosis. The purpose of this study was to assess the diagnostic value of CCN1 and CCN3 expressions for PsA. Patients and methods: Thirty-seven PsA patients, 37 psoriasis patients, and 37 matched healthy controls participated in a case-control study. ELISA was used to detect protein levels while qRT-PCR was used to evaluate gene expression. Results: Patients with PsA and psoriasis had greater serum and expression levels of CCN1 compared to controls (p< 0.0001). Patients with PsA and psoriasis had greater serum and expression levels of CCN1 compared to controls (p= 0.003, p< 0.0001). Both CCN3 levels in PsA patients were greater than in controls (p< 0.0001), but patients with psoriasis did not significantly differ from controls (p=0.13, p=0.38). When compared to psoriasis patients, PsA patients had greater serum and expression levels of CCN3 (p< 0.0001). In terms of psoriasis duration and severity, CCN1 exhibited a positive relation. It was shown that CCN3 and both the duration and severity of arthritis correlated positively. All markers were positively correlated with inflammatory markers. Conclusions: The most accurate marker for PsA detection was CCN3 expression, followed by the serum level of CCN1. However, CCN1 expression was the most accurate marker for the differentiation between psoriasis and PsA, followed by CCN3 expression. CCN3 could be a marker for PsA severity. These preliminary data need further studies to confirm their findings.

show abstract

CCN1, a novel RA target?

Cited by 6 publications

References 1 publication

Melatonin serves as a novel treatment in cystic fibrosis and inhibits cystic fibrosis through TGF-β1/Smad and EMT

Melatonin serves as a novel treatment in cystic fibrosis and inhibits cystic fibrosis through TGF-β1/Smad and EMT

The Roles of CCN1/CYR61 in Pulmonary Diseases

Peripheral Blood mRNA and Protein Levels of CCN1 and CCN3 in Psoriatic Arthritis: A Case-Control Study

Contact Info

Product

Resources

About